Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.48 (transcriptase)
 9,479 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

MicroRNAs (miRNAs) have been demonstrated to be critical players in different types of tumors including gastric cancer (GC). However, the expression level of serum miR-647 in patients with GC and its potential prognostic significance were poorly known. The aim of this study was to investigate the clinical significance of serum miR-647 in GC. A total of 105 patients with GC and 50 healthy volunteers were recruited into this study. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was used to analyze the expression of serum miR-647. Diagnostic accuracy of serum miR-647 in distinguishing GC patients from healthy controls was assessed by the receiver operating characteristic (ROC) curve analysis. Chi-square was used to evaluate the association between serum miR-647 level and clinicopathologic parameters. Kaplan-Meier method was used to analyze the overall survival (OS) and relapse-free survival (RFS). Multivariate Cox proportional hazards analyses were further used to identify prognostic factors. Our results showed that a significantly downregulated expression of serum miR-647 was found in patients with GC. ROC curve analyses showed that serum miR-647 was highly efficient for discriminating patients with GC from healthy controls. In addition, low serum miR-647 expression was associated with aggressive clinical features and unfavorable survival in GC. Mechanistically downregulation of miR-647 in GC cell lines increased the expression levels of STX6, STX7, and PRKCA. In conclusion, our results demonstrate that serum miR-647 might serve as a novel serum biomarker for monitoring GC progression.
 ...
PMID:Decreased expression of serum miR-647 is associated with poor prognosis in gastric cancer. 3193 82